Chai Discovery, an AI company developing a computer-aided design suite for molecules, is collaborating with Novartis to advance the discovery of therapeutic antibodies using AI Under the collaboration ...
Beckman Coulter Diagnostics, a specialist in clinical diagnostics and a Danaher company, has received CE Mark under IVDR for its Acess p-Tau217 assay, a blood test designed to support the clinical ...
AdJane, a clinical-stage vaccine platform company developing intranasal and intramuscular vaccines based on native Outer Membrane Vesicles (nOMVs), has published first-in-human Phase I clinical data ...
Osteosarcoma is an aggressive bone cancer characterised by high rate of recurrence and metastasis. It is the most common primary bone cancer in children, adolescents and young adults. Symptoms include ...
CDMO partner Freudenberg Medical recently launched CleanAssure, an ISO Class 5 controlled cleanroom for sterile single-use assemblies. The cleaning and sterilisation service supports biopharmaceutical ...
A recent study published in Neurology has developed an AI tool to improve diagnostics accuracy in Alzheimer’s disease and related dementias. The results showed that AIDD identified the two diseases ...
Biotechnology company Nuclera has introduced an antibody screening service to enable quick access to high-quality proteins and advance AI-driven discovery. “Antibodies are one of the most important ...
Waters Corporation has launched a the Xevo MRT P10 mass spectrometer, a high-resolution Quadrupole Time-of-Flight (QToF) system for high-throughput multiomics, bioanalysis and biopharmaceutical ...
Women’s health medical technology company Calla Lily Clinical Care has dosed the first patients in the Freedom clinical trial. The study is evaluating 400mg progesterone Callavid in patients diagnosed ...
Lundbeck will be presenting its research at the 2026 Alzheimer’s and Parkinson’s Disease conference Lundbeck has shared that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel ...
Independent European studies presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 and Alzheimer’s & Parkinson’s Disease Conference (ADPD) 2026 confirmed that the HISCL p-Tau217 RUO and ...
CCRM and CDMO subsidiary OmniaBio have partnered with Avectas to evaluate its automated, integrated, and scalable cell therapy manufacturing platform. The evaluation will explore how Avectas’ platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results